top of page
LUTETIA THERAPEUTICS

Turning multimodal science into progress for patients.

Lutetia Therapeutics is advancing LUT001 (formerly PXT3003) for CMT1A while building a research portfolio of next-generation combination therapies for CMT1A, ALS and Alzheimer’s disease.

Established in 2026.

WHY WE EXIST

For what matters in everyday life.

Our work is guided by what matters beyond a clinical endpoint: the everyday realities, hopes and challenges of people living with neurological diseases and their families.

Mobility

Restoring the ability to move and engage with the world with greater confidence and comfort.

Independence

Preserving the freedom to live life on one's own terms, with less reliance on others for daily tasks.

Connection

Staying connected to the people and communities who matter most, without the limitations imposed by symptoms.

Complex diseases. Complementary mechanisms.

Our approach investigates how complementary therapeutic mechanisms can work together to address the biological complexity of neurological disease. Our goal is to develop treatments that help preserve function and everyday independence. Each combination must be evaluated on its own scientific and clinical evidence.

OUR LEAD PROGRAM

LUT001 for CMT1A

LUT001 (formerly PXT3003) is an investigational low-dose oral combination with a development history spanning Phase 2, Phase 3 studies and long-term follow-up. PLEO-CMT reported a favorable result; PREMIER showed trends of efficacy; a separate China Phase 3 study reported a positive primary endpoint. Lutetia is assessing the complete record to define the next development strategy.

One lead program.
Three research priorities.

LUT001 anchors our development strategy. Our research priorities extend into next-generation CMT1A, ALS and Alzheimer’s disease.

Next-generation CMT1A

Explore combinations and novel components that could build on the LUT001 approach.

LUT002 — ALS

Investigate multimodal strategies addressing complementary disease mechanisms in amyotrophic lateral sclerosis.

LUT003 — Alzheimer’s disease

Explore rational combinations for complex disease biology.

An international ambition. An evidence-led path.

Lutetia is preparing its development strategy for the United States and Europe, with Japan under evaluation. Clinical evidence, manufacturing requirements and regulatory feedback will guide the next decisions.

The China program is led separately by Tasly/GeneNet.

STRATEGIC DISCOVERY COLLABORATION

Complementary strengths. Shared ambition.

Lutetia Therapeutics

×

Tangramed

In September 2026, Lutetia and Tangramed signed a framework term sheet for a discovery collaboration in next-generation CMT1A, ALS and Alzheimer’s disease.

Discuss the opportunity with Lutetia

We welcome conversations with investors, biopharma partners and scientific collaborators interested in advancing neurological therapies.

bottom of page